FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1
These resources can be used to support you and your patients or to help support you when making prescribing decisions:
Forxiga® (dapagliflozin) Patient Information Sheet
A leaflet for your patients: Your new medicine: how it works and what to look out for.
Dealing with setbacks in type 2 diabetes
This Leaflet has been developed by AstraZeneca as a supporting document to help patients stayfocused and manage their diabetes more effectively.
Managing food, weight and emotions in type 2 diabetes
This Leaflet explains some of the reasons patients would struggle to understand their relationship with food and provides practical strategies to overcome these issues.
Prepare for a Healthy Ramadan
This leaflet provides information on what you should know about managing type 2 diabetes during Ramadan.